亚太药业
(002370)
| 流通市值：47.65亿 | | | 总市值：47.65亿 |
| 流通股本：7.46亿 | | | 总股本：7.46亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 59,576,342.35 | 323,136,959.51 | 228,305,775.2 | 152,074,731.41 |
| 营业收入 | 59,576,342.35 | 323,136,959.51 | 228,305,775.2 | 152,074,731.41 |
| 二、营业总成本 | 61,867,871.14 | 368,315,692.88 | 281,658,163.74 | 197,899,171.63 |
| 营业成本 | 38,399,298.48 | 216,139,876.06 | 157,403,051.95 | 103,933,891.68 |
| 税金及附加 | 1,120,727.85 | 5,578,936.66 | 4,107,666.04 | 2,595,471.25 |
| 销售费用 | 10,757,854.98 | 52,548,016.64 | 37,553,136.05 | 25,558,766.57 |
| 管理费用 | 10,213,330.03 | 52,562,158.12 | 43,068,718.53 | 28,241,851.01 |
| 研发费用 | 3,291,867.82 | 15,467,732.77 | 11,631,686.36 | 6,906,516.81 |
| 财务费用 | -1,915,208.02 | 26,018,972.63 | 27,893,904.81 | 30,662,674.31 |
| 其中:利息费用 | - | 34,704,751.21 | 34,642,973.19 | 34,642,973.19 |
| 其中:利息收入 | 1,919,083.47 | 8,738,770.8 | 6,772,563.36 | 4,003,460.59 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -1,704,336.58 | 830,085.38 | -492,719.88 | 952,429.21 |
| 加:投资收益 | 101,716.15 | 150,238,962.52 | 150,238,252.18 | 150,281,649.56 |
| 资产处置收益 | - | -57,942.49 | - | - |
| 资产减值损失(新) | -2,368,761.17 | -23,103,284.03 | -5,029,349 | -5,029,349 |
| 信用减值损失(新) | -271,742.87 | 858,982.13 | 386,704.63 | 865,162.2 |
| 其他收益 | 3,738,236.85 | 6,920,283.12 | 5,509,405.28 | 5,134,661.94 |
| 四、营业利润 | -2,796,416.41 | 90,508,353.26 | 97,259,904.67 | 106,380,113.69 |
| 加:营业外收入 | 3,592.8 | 7,200,776.15 | 979,776.85 | 57,797.8 |
| 减:营业外支出 | 50,356.59 | 1,276,788.95 | 1,118,577.3 | 1,118,577.3 |
| 五、利润总额 | -2,843,180.2 | 96,432,340.46 | 97,121,104.22 | 105,319,334.19 |
| 减:所得税费用 | -255,650.49 | 124,512.81 | -73,908 | 142,864.37 |
| 六、净利润 | -2,587,529.71 | 96,307,827.65 | 97,195,012.22 | 105,176,469.82 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -2,587,529.71 | 96,307,827.65 | 97,195,012.22 | 105,176,469.82 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -2,587,529.71 | 96,307,827.65 | 97,195,012.22 | 105,176,469.82 |
| 扣除非经常损益后的净利润 | -4,368,585.08 | -64,687,770.15 | -56,585,337.63 | -48,862,245.08 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | 0.13 | 0.13 | 0.14 |
| (二)稀释每股收益 | 0 | 0.13 | 0.13 | 0.14 |
| 九、综合收益总额 | -2,587,529.71 | 96,307,827.65 | 97,195,012.22 | 105,176,469.82 |
| 归属于母公司股东的综合收益总额 | -2,587,529.71 | 96,307,827.65 | 97,195,012.22 | 105,176,469.82 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-29 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |